Am J Transplant, Volume 18, Suppl 3 Archives - Page 67 of 211 - ATC Abstracts

2018 American Transplant Congress
Designing Novel Selective Immunoproteasome Inhibitors Reveals a Critical Role of the Immunoproteasome in Protecting Antibody Secreting B Cells from Apoptosis
J. Assaker,¹ N. Murakami,¹ S. Eskandari,¹ M. Uehara,¹ C. Nathan,² H. Li,³ G. Lin,² J. Azzi.¹
¹Transplantation Renal Center, Harvard Medical School, Boston; ²Microbiology and Immunology, Weill Cornell Medicine, New York; ³Cryo-EM Structural Biology Laboratory, Van Andel Research Institute, Grand Rapids.
Constitutive proteasomes (c-20S) are ubiquitously-expressed cellular proteases that degrade polyubiquitinated proteins and regulate cell functions. Its inhibitor, bortezomib, is a plasma cell-targeted therapy used in…
2018 American Transplant Congress
Improvement of Metabolic Function after Intra-Portal Allogeneic Islet Transplantation by Induction Treatment of the Non-Hematopoetic Erytropoetin Analogue Cibinetide in a Mouse Model
M. Yao,¹ M. Watanabe,^1,2 S. Sun,¹ B. Ericzon,¹ T. Lundgren,¹ M. Kumagai-Braesch.¹
¹Department of Transplantation Surgery, Karolinska University Hospital, Stockholm, Sweden; ²Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
IntroductionRecently, we have demonstrated that cibinetide, a non-hematopoetic erytropoetin analogue, protected pancreatic islets from cytokine-induced damage and apoptosis and ameliorated the early inflammatory response following…
2018 American Transplant Congress
The TRANSFORM Study: Infection Outcomes with Everolimus Plus Reduced Calcineurin Inhibitor and Mycophenolate Plus Standard Calcineurin Inhibitor Regimens in De Novo Kidney Transplant Recipients
F. Vincenti, J. Cruzado, S. Mulgaonkar, V. Garcia, D. Kuypers, M. Buchler, F. Citterio, U. Huynh-Do, W-.L. Luo, P. Bernhardt, C. Sommerer.
TRANSFORM Study Group, Novartis Pharma AG, Basel, Switzerland.
Purpose: Post-transplant (Tx) bacterial and viral infections are known to affect graft and patient survival. Accumulating evidence supports the protective effect of everolimus (EVR) against…
2018 American Transplant Congress
Renal Function, Blood Pressure, and Histologic Changes in Living Kidney Transplant Recipients from Hypertensive Donors
T. Dienemann, J. Schellenberg, K. Amann, K. Heller, A. Weidemann.
Nephrology and Hypertension University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.
Little is known if a kidney from a hypertensive donor performs equally compared to a kidney from a non-hypertensive donor. The present study examines the…
2018 American Transplant Congress
Clinical Application of Mesenchymal Stromal Cells with a Simplified Protocol for ABO Incompatible Liver Transplantation in Severe Hepatic Failure Patients
Y. Zhang,^1,2 J. Zheng,^1,2 J. Cai,^1,2 J. Zhang,^1,2 K. Zeng,^1,2 J. Yao,^1,2 Y. Yang.^1,2
¹Department of Hepatic Surgery and Liver Transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Guangzhou, Guangdong, China; ²Guangdong Key Laboratory of Liver Disease Research, Key Laboratory of Liver Disease Biotherapy and Translational Medicine of Guangdong Higher Education Institutes, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, .
Objective The purpose of this study was to test the safety and efficacy of mesenchymal stromal cells (MSCs) treatment with a simplified protocol for ABO…
2018 American Transplant Congress
Increased Pre-Transplant Rejection-Risk Measured with Allospecific T-Cells Predicts Delayed Immunosuppression Minimization in Children with Intestine Transplantation.
K. Soltys, C. Ashokkumar, G. Mazariegos, G. Bond, M. Ningappa, A. Khanna, A. Ganoza, Q. Sun, R. Sindhi.
Pediatric Abdominal Transplant, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA.
BACKGROUND: Allospecific CD154+T-cytotoxic memory cells (CD154+TcM) are used clinically to predict acute cellular rejection (ACR) after intestine transplantation (ITx) in children <21 years old within…
2018 American Transplant Congress
Type I NKT Cells Augment Humoral and Cellular Alloimmunity in Response to Hepatocyte Transplantation
S. Elzein, J. Zimmerer, B. Ringwald, C. Avila, G. Bumgardner.
Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.
Hepatocyte transplantation (HcTx) is a potential therapeutic modality for patients with liver disease. Despite examples of antigen acceptance in the liver, allogeneic HcTx into patients…
2018 American Transplant Congress
Outcomes of DCD Renal Transplantation from Donors with Acute Kidney Injury
E. Grodstein, J. Yang, V. Nair, L. Teperman.
Northwell Health, Manhasset, NY.
BackgroundDeceased donor kidneys with acute kidney injury (AKI) are a viable source of organs, yet are frequently discarded. Outcomes of deceased donor renal transplantation (DDRT)…
2018 American Transplant Congress
Is Age a Potential Barrier to Pursuing Living Donor Kidney Transplant (LDKT)?
A. Raissi, N. Edwards, Y. Liao, D. Belenko, N. Singh, M. Khalid, D. Toews, I. Mucsi.
Multi-Organ Transplant Program, Department of Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
BackgroundThe incidence of end stage kidney disease (ESKD) among older adults (65+) is increasing. Living Donor Kidney Transplant (LDKT) may provide improved outcome even for…
2018 American Transplant Congress
A Medical Decision Analysis for the Use of Donation after Cardiac Death Donors for Simultaneous Liver-Kidney Transplant
A. Miller, K. Tennankore, B. Kiberd.
Division of Nephrology, Department of Medicine, Dalhousie University, Halifax, NS, Canada.
For patients on the simultaneous liver-kidney transplant (SLKT) waitlist, acceptance of donation after cardiac death (DCD) organs may facilitate earlier transplantation thereby reducing waitlist mortality,…